DNA-PK mutations have been associated with a high TMB and high ICI response rates in several human cancers, and a DNA-PKi enhanced the efficacy of PD-1 pathway blockade in a murine colon cancer model [142]. The gene discussed is PDCD1; the disease is cancer.